ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced two poster presentations and one ...

Patients saw improved event-free survival and overall survival with presurgical Imfinzi and chemotherapy followed by surgery and postsurgical Imfinzi. Treatment with Imfinzi (durvalumab) before and ...

AstraZeneca’s IMFINZI ® (durvalumab) in combination with Bacillus Calmette-Guérin (BCG) induction and maintenance therapy has been approved in the US for the treatment of adult patients with BCG-naïve ...

Combination significantly improved disease-free survival in phase III trial ...

Natera, Inc. NTRA recently announced the FDA approval of Signatera CDx as a companion diagnostic (CDx) for use with adjuvant atezolizumab (Tecentriq) immunotherapy in patients with muscle-invasive ...

Patrick Hensley, MD and Daniel Joyce, MD, MS each received a grant up to $50,000.00 to support the development of outstanding clinical cancer research to improve the treatment of NMIBCLast year’s ...

Stock Moves Higher Following Patent AnnouncementShares of ImmunityBio (NASDAQ:IBRX) gained 4. 5% in premarket trading on ...

NMIBC treatment varies by tumor stage, grade, and prior therapies, with high-risk cases often requiring radical cystectomy. Bladder-preserving approaches include intravesical therapies like BCG, ...

ImmunityBio (NasdaqGS:IBRX) presented new clinical data on ANKTIVA in advanced non small cell lung cancer and BCG unresponsive non muscle invasive bladder cancer at the 2026 ASCO Annual Meeting. The ...

Recurrences of low-, intermediate-, or high-/very high-risk tumors were again low, intermediate, or high risk in 74%, 62%, and 44% of cases, respectively. Recurrent non-muscle invasive bladder cancer ...